Axonics (AXNX: NASDAQ) Investor Relations Material

Overview

Medical technology company Axonics, Inc. is making waves in the field of bladder and bowel dysfunction with its innovative products. The company specializes in developing and commercializing novel treatments for patients suffering from overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Axonics' sacral neuromodulation (SNM) systems are designed to deliver mild electrical pulses to the targeted sacral nerve, thereby reducing the symptoms of bladder and bowel dysfunction. These SNM systems are available in both rechargeable and recharge-free models. In addition to its SNM systems, Axonics also offers Bulkamid, a urethral bulking agent specifically designed to treat female stress urinary incontinence. The company sells its products through a combination of direct sales and distributor partnerships across the United States, the United Kingdom, Germany, the Netherlands, the Nordic countries, and other international markets. Since its inception in 2012, Axonics has been committed to advancing medical technology solutions that deliver tangible patient benefits. The company, formerly known as Axonics Modulation Technologies, Inc., recently underwent a name change to Axonics, Inc. in March 2021. With its headquarters in Irvine, California, Axonics is poised to continue driving innovation in the field of bladder and bowel dysfunction treatment.